Life Stem Genetics (OTCBB:LIFS) is pleased to announce that it has
completed and received the first $500,000 of the recently announced $1mm
Private Placement. Our company is very happy to receive the first half
of our recent private placement and hopes to close the additional
$500,000 in the coming weeks.
The money will be used to attract additional affiliate offices country
wide and to invest in various areas of research and development in
moving our company's plans forward.
About Life Stem Genetics
Life Stem Genetics (“LSG”) is a progressive health care company that
focuses on healing with a patient’s own “Stem Cells.” Stem Cells for
years have been known to heal a variety of ailments successfully and now
it is being offered as an efficient and painless way to treat many
different illnesses ranging from orthopedic injuries, neurological
disorders such as Parkinson’s and Alzheimer’s, Cancer, Plastic Surgery,
Age Management, Arthritis, Diabetes, Cardiology, COPD, MS, Urology, and
many more. Stem Cell Therapy and LSG’s proprietary techniques have
experienced some of the best results in the industry, helping to repair
or re-program damaged or diseased tissues and organs.
LSG’s stem cell specialist has performed thousands of stem cell
treatments, including the top names in PGA golf, NFL football, NBA
basketball, and Major League Baseball. LSG will offer their proprietary
treatments through a series of affiliate doctors, and medical clinics,
with 60 affiliated clinics so far.
LSG’s mission is to create a solid comprehensive approach to the
treatment and maintenance of diseases and to break free from the medical
insurance world by tapping into an affordable private-pay sector
delivering exceptional healthcare free from the medical insurance maze.
http://www.lifestemgenetics.com/
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities
Litigation Reform Act of 1995 that are not historical facts. These
statements can be identified by the use of forward-looking terminology
such as "believe," "expect," "may,” “could,” “estimates,” "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology, and include discussions of
strategy, and statements about industry trends and the Company's future
performance, operations, and products. Such statements involve known and
unknown risks, uncertainties and other factors that could cause the
Company's actual results to differ materially from the results expressed
or implied by such statements. Such risks and uncertainties include,
without limitation, market acceptance of the Company's stem cell therapy
treatment program; the Company's compliance with applicable statutes and
regulations: the Company's reliance on third-party contractors to
provide suitable treatment facilities; the Company's ability to expand
its network of participating clinics and doctors; the Company's ability
to develop an effective marketing strategy; the Company's ability to
control and reduce advertising and marketing costs; the Company's
ability to develop and increase awareness of its brand; the Company's
ability to protect its trademarks; and the success of the Company's
marketing focus to patients, doctors and clinics. For a discussion of
these and other risks and uncertainties see "Risk Factors" and
“Description of Business” in the Company's public filings with the SEC.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, there can be no assurance
that such expectations will prove to be correct. The Company has no
obligation to update the forward-looking information contained in this
press release.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20131022005634r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2013